Novartis Inks Up to $7.8B RNA Therapeutics Deal With Abogen
NVS sits 16% above its 52-week low of $121.57.
Summary
Novartis has entered a collaboration with Abogen Biosciences potentially worth up to $7.8 billion to develop RNA-encoded therapeutics. The deal expands Novartis's pipeline in a high-growth modality and follows a series of clinical setbacks in its late-stage portfolio, including failed trials for pelacarsen and del-desiran. This partnership signals a strategic pivot toward next-generation RNA platforms and could provide a new avenue for pipeline replenishment. The financial terms are substantial relative to typical early-stage collaborations, indicating strong commitment. Investors will watch for further details on target indications and milestone structure.
At the time of this announcement, NVS was trading at $141.05 on NYSE in the Life Sciences sector, with a market capitalization of approximately $259.9B. The 52-week trading range was $121.57 to $170.46. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.